Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Gross Profit (2023 - 2025)

Krystal Biotech (KRYS) has disclosed Gross Profit for 3 consecutive years, with $100.5 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 16.62% to $100.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $366.0 million through Dec 2025, up 35.34% year-over-year, with the annual reading at $366.1 million for FY2025, 35.35% up from the prior year.
  • Gross Profit hit $100.5 million in Q4 2025 for Krystal Biotech, up from $93.5 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $100.5 million in Q4 2025 to a low of $8.3 million in Q3 2023.
  • Historically, Gross Profit has averaged $68.4 million across 3 years, with a median of $80.1 million in 2024.
  • Biggest five-year swings in Gross Profit: soared 825.43% in 2024 and later rose 16.62% in 2025.
  • Year by year, Gross Profit stood at $39.3 million in 2023, then surged by 119.4% to $86.2 million in 2024, then rose by 16.62% to $100.5 million in 2025.
  • Business Quant data shows Gross Profit for KRYS at $100.5 million in Q4 2025, $93.5 million in Q3 2025, and $88.8 million in Q2 2025.